title: Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma.
abstract: Clinical and radiological diagnosis of infantile fibrosarcoma (IFS) is challenging because of its similarity to vascular origin tumors. Treatment involves complete resection. Although chemotherapy may allow more conservative resection, treatment guidelines are not strictly defined. One IFS patient with an unresectable tumor had disease progression during chemotherapy. A primary tumor sample showed high VEGFR-1/2/3 and PDGFR-α/β expression. After pazopanib therapy, most tumor showed necrosis within 29 days and could be removed completely, with no relapse in 8 months post-resection. When IFS features hypervascularity, VEGFR and PDGFR expression may be high, thus allowing consideration of VEGFR inhibitors such as pazopanib.
authors.affiliation: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.|Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Ryu
authors.initials: R
authors.lastname: Yanagisawa
authors.affiliation: Department of Plastic and Reconstructive Surgery, Nagano Children's Hospital, Azumino, Japan.
authors.forename: Masahiko
authors.initials: M
authors.lastname: Noguchi
authors.affiliation: Department of Plastic and Reconstructive Surgery, Nagano Children's Hospital, Azumino, Japan.
authors.forename: Kenya
authors.initials: K
authors.lastname: Fujita
authors.affiliation: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.|Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Sakashita
authors.affiliation: Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Sano
authors.affiliation: Department of Clinical Pathology, Nagano Children's Hospital, Azumino, Japan.
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Ogiso
authors.affiliation: Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan.
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Katsuyama
authors.affiliation: Department of Radiology, Nagano Children's Hospital, Azumino, Japan.
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kondo
authors.affiliation: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.|Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Komori
authors.affiliation: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.
authors.forename: Ikuko
authors.initials: I
authors.lastname: Fujihara
authors.affiliation: Division of Neonatology, Nagano Children's Hospital, Azumino, Japan.
authors.forename: Rei
authors.initials: R
authors.lastname: Kitamura
authors.affiliation: Division of Neonatology, Nagano Children's Hospital, Azumino, Japan.
authors.forename: Takehiko
authors.initials: T
authors.lastname: Hiroma
authors.affiliation: Department of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.|Division of Neonatology, Nagano Children's Hospital, Azumino, Japan.|Life Science Research Center, Nagano Children's Hospital, Azumino, Japan.
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Nakamura
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001365:Axilla / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007191:Indazoles; D007223:Infant; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods*; D011743:Pyrimidines / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D017479:Receptors, Platelet-Derived Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor
keywords: infantile fibrosarcoma; pazopanib; platelet-derived growth factor receptor; vascular endothelial growth factor receptor